PROSTANOIDS are metabolites of arachidonic acid through the activity of cyclooxygenase (COX)
PROSTANOIDS are metabolites of arachidonic acid through the activity of cyclooxygenase (COX). COX exists in two major isoforms: constitutive COX-1 and inducible COX-2. PGE 2 is the major prostanoid produced in the kidney, and it induces biological function by binding to four G protein-coupled receptors (EP 1 -EP 4 ), which each couple to a distinct signaling pathway. COX-derived prostanoids affect a wide spectrum of renal function in health and disease (2) .
Obstructive nephropathy is a common cause of chronic kidney disease in both children and adults. In addition, unilateral ureteral obstruction (UUO) readily induces tubulointerstitial fibrosis, a common pathophysiology of chronic kidney disease, irrespective of the causes, which leads to the end stage of renal disease (1) . Accordingly, UUO in rodents is a widely used experimental model of renal fibrosis. It has been reported that PGE 2 generation is elevated in obstructed kidneys (10, 12) . The heightened PGE 2 synthesis is associated with increased COX-2 expression in the UUO model (4, 8) . In vitro evidence demonstrates that COX-2 expression in renal medullary interstitial cells is increased in response to pressure, dependent on the endogenous production of ROS (3, 11) . ROS dependence of COX-2 induction was also observed in rats subjected to UUO (11) . A number of studies using pharmacological inhibitors of COX-2 have attempted to address the functional role of COX-2 in UUO but have yielded inconclusive results. UUOinduced renal fibrosis, as assessed by the expression of collagen types I, III, and IV, was exaggerated by the administration of celecoxib, a specific COX-2 inhibitor (8) . In parallel, mRNA expression of transforming growth factor-␤, a major profibrogenic factor, also increased in the celecoxib-treated group compared with the vehicle-treated control group (8) . These results suggest a protective role of COX-2 against tubulointerstitial fibrosis during UUO. Conversely, inhibition of COX-2 with meloxicam attenuated extracellular matrix protein syntheses in stretched fibroblasts and tubulointerstitial fibrosis in UUO (5, 15) . While celecoxib is more selective than meloxicam, the conflicting results obtained with the two inhibitors obviously necessitates validations using a genetic approach.
In a recent issue of the American Journal of Physiology-Renal Physiology, Nilsson et al. (9a) used COX-2 knockout (KO) mice to clarify the role of COX-2 in the development of several injurious indexes induced by UUO. The authors were aware of the pathological changes in the COX-2 KO kidney, a developmental phenotype that may confoundingly influence obstruction-induced kidney injury. Accordingly, the authors chose COX-2 KO mice on a mixed 129/C57 background at the age 10 -14 wk in this study since these animals did not exhibit differences in blood pressure, urine concentrating capability (14) , or indexes of oxidative stress, apoptosis, or tubular injury under basal conditions compared with wild-type (WT) control mice. It is known that the renal phenotype in COX-2 KO mice is dependent on genetic background and age (14) . COX-2 KO and WT mice underwent UUO for 3 and 7 days, and parameters of oxidative stress [heme oxygenase (HO)-1, SOD1, and SOD2], apoptosis (TUNEL staining and caspase-3), and tubular injury (histology and kidney injury molecule-1) were determined. Consistent findings showed the indexes of these three categories of tissue injury were induced by UUO in WT mice, all of which were exaggerated in COX-2 KO mice. These results represent the first genetic evidence to prove a protective role of COX-2 against renal injury in UUO.
This study has a number of limitations. ROS have been postulated to be a major molecular target of COX-2-derived prostaglandins in UUO. However, the assessment of ROS production in the obstructed kidney is insufficient. The expression level of HO-1, SOD1, and SOD2 has been determined to indirectly reflect ROS production. Direct measurement of ROS production using methods such as the electron paramagnetic resonance spin-trapping technique will be extremely helpful. The COX-2 KO kidney exhibits a greater increase in the expression of antioxidant genes such as HO-1, SOD1, and SOD2 compared with WT control kidneys after UUO. However, the causal relationship between COX-2 deletion and the antioxidant gene upregulation is unclear. The detailed mechanism of how COX-2-derived prostaglandins affect a specific antioxidant gene awaits further investigations.
In a sharp contrast to the protective role of COX-2 in UUO as descried above, COX-2 plays a pathogenic role in other models of kidney injury, such as cisplatin nephropathy. In a mouse model of cisplatin nephrotoxicity, renal expression of COX-2 and microsomal prostaglandin synthase-1 was elevated accompanied with increased PGE 2 levels (7) . Inhibition of prostaglandin synthesis by celecoxib or meloxicam or by microsomal prostaglandin synthase-1 deletion consistently attenuated cisplatin-induced renal dysfunction, oxidative stress, and inflammation (6, 7) . It is interesting to note that even in the same model of UUO, macrophage COX-2 has been shown to mediate renal inflammation, oxidative stress, and apoptosis (13) . In this study, a novel technique involving the use of chitosan/small interfering RNA nanoparticles was successfully used to achieve macrophage-specific knockdown of COX-2 (13) . This technique helps address the pathogenic role of macrophage COX-2 during UUO and also represents a novel intervention for the management of obstructive nephropathy. This study also brings up a question as to the cell type responsible for the protective role of COX-2, which should be distinct from macrophages. EP 4 has been shown to mediate the protective role of COX-2 against UUO-induced tubulointerstitial fibrosis (9) . It will be interesting to determine the EP subtype responsible for the pathogenic role of COX-2 in kidney injury.
In summary, COX-2 deletion in mice exacerbates obstructioninduced renal oxidative stress, apoptosis, and tubular injury. These results represent a strong genetic evidence supporting a protective role of COX-2 against obstructive nephropathy. Such protective action of COX-2 is likely mediated by the PGE 2 /EP 4 pathway (Fig. 1) . COX-2 inhibitors should be used with caution in patients with this disease. 
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